Trials
2 active
3 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Single infusion of 4×10\^6 cells/kg of LMY-920 (autologous CAR-T cell therapy expressing the BAFF-ligand.)”In the company’s words, NCT07771361 on ClinicalTrials.gov
- Tested for
- Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Non-Hodgkin Lymphoma, B-cell, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma in Remission and 1 more
- Main trialPhase 2
- “Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This Phase 2 study will establish the safety and efficacy profile of LMY-920.”In the company’s words, NCT07771361 on ClinicalTrials.gov
- Other names
- BAFF CAR-T
Other drugs for Non-Hodgkin Lymphoma Refractory/ Relapsed
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
- AcalabrutinibAstraZeneca · Phase 3
- EpcoritamabGenmab · Phase 3
- SHR-A1912Hengrui · Phase 3
- TisagenlecleucelNovartis · Phase 3
Coming up1
- Dec 2030Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Dec 2030 | BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma | |
| Phase 1Recruiting | 15 Apr 2026 | BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus | |
| Phase 1Unknown | 1 May 2025 | Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026